Savara, Inc. (SVRA)
Stock Price:
$1.09 USD
-0.06 (-4.82%)
Updated Oct 28, 2020 12:43 PM EDT - Market open
Key Info
| Market Cap |
58.73M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-68.93M |
| Shares Out |
54.13M |
| EPS (ttm) |
-1.37 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$1.09 |
| Previous Close |
$1.14 |
| Change ($) |
-0.06 |
| Change (%) |
-4.82% |
| Day's Open |
1.12 |
| Day's Range |
1.05 - 1.12 |
| Day's Volume |
178,328 |
| 52-Week Range |
0.69 - 5.48 |
More Stats
| Market Cap |
58.73M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
54.13M |
| Float |
40.10M |
| EPS (basic) |
-1.48 |
| EPS (diluted) |
-1.37 |
| FCF / Share |
-0.72 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.03M |
| Short Ratio |
4.60 |
| Short % of Float |
2.57% |
| Beta |
1.05 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
0.76 |
| Revenue |
n/a |
| Operating Income |
-69.46M |
| Net Income |
-68.93M |
| Free Cash Flow |
-42.23M |
| Net Cash |
74.75M |
| Net Cash / Share |
1.38 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-23.22% |
| ROE |
-70.13% |
| ROIC |
-66.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.43*
(308.29% upside)
Low
1.30
Current: $1.09
High
7.00
Target: 4.43
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | 0.40 | 0.05 |
| Revenue Growth | - | - | - | 640.74% | - |
| Gross Profit | - | - | - | 0.40 | 0.05 |
| Operating Income | -79.03 | -70.05 | -29.96 | -10.95 | -5.92 |
| Net Income | -78.17 | -61.52 | -29.80 | -10.92 | -9.00 |
| Shares Outstanding | 40.03 | 33.30 | 17.52 | 1.96 | 0.97 |
| Earnings Per Share | -1.95 | -1.85 | -1.76 | -5.62 | -9.48 |
| Operating Cash Flow | -45.12 | -39.28 | -28.23 | -8.37 | -4.78 |
| Capital Expenditures | -0.15 | -0.14 | -0.50 | -0.01 | - |
| Free Cash Flow | -45.27 | -39.42 | -28.73 | -8.38 | -4.78 |
| Cash & Equivalents | 122 | 111 | 94.31 | 13.37 | - |
| Total Debt | 25.11 | 24.53 | 15.34 | 4.47 | - |
| Net Cash / Debt | 96.65 | 86.30 | 78.98 | 8.90 | - |
| Assets | 136 | 152 | 160 | 28.93 | - |
| Liabilities | 34.51 | 44.07 | 40.32 | 20.95 | - |
| Book Value | 102 | 108 | 119 | -35.88 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Savara, Inc. |
| Country |
United States |
| Employees |
46 |
| CEO |
Matthew Pauls |
Stock Information
| Ticker Symbol |
SVRA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SVRA |
Description
Savara operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; and in Phase IIa development stage for treating nontuberculous mycobacterial lung infection. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis. Savara Inc. is headquartered in Austin, Texas.